医学
免疫疗法
肺癌
淋巴结切除术
癌症
肿瘤科
肺
内科学
外科
呼吸道疾病
放射科
作者
Masaya Aoki,Go Kamimura,Yusei Tsuneyoshi,Shoichiro Morizono,Takuya Tokunaga,Aya Harada-Takeda,Koki Maeda,Toshiyuki Nagata,Kota Kariatsumari,Kazuhiro Ueda
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2025-08-28
卷期号:45 (9): 3971-3981
被引量:3
标识
DOI:10.21873/anticanres.17755
摘要
BACKGROUND/AIM: Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for recurrent non-small cell lung cancer (NSCLC). However, the factors predicting their efficacy in postoperative recurrence remain unclear. PATIENTS AND METHODS: We retrospectively analyzed 30 patients who underwent complete surgical resection of NSCLC and subsequently received ICI monotherapy for recurrence. Clinicopathological factors, including the programmed death ligand 1 (PD-L1) expression and number of dissected lymph nodes (DLNs), were evaluated for their association with the treatment response and prognosis. RESULTS: The high expression of PD-L1 (≥50%) in surgical specimens was significantly associated with higher response rates, prolonged progression-free survival (PFS), and overall survival (OS) after the initiation of ICI therapy. In contrast, patients with ≥15 DLNs had a significantly shorter PFS than those with <15 DLNs, particularly in patients without extrathoracic recurrence. A multivariate analysis identified the expression of PD-L1, the number of DLNs, and the presence of extrathoracic metastasis as independent prognostic factors for ICI-PFS. CONCLUSION: Extensive lymphadenectomy may worsen the prognostic outcomes of ICI monotherapy, possibly by impairing tumor-draining lymph node-mediated immunity. These findings highlight the importance of lymphatic preservation and support the clinical rationale for neoadjuvant ICI therapy for resectable NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI